<DOC>
	<DOCNO>NCT00070083</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy , cyclophosphamide , doxorubicin , vincristine , prednisone , use different way stop cancer cell divide stop grow die . Oblimersen may increase effectiveness chemotherapy drug make cancer cell sensitive drug . Combining oblimersen rituximab combination chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best dose oblimersen give together rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone treat patient stage II , stage III , stage IV large B-cell lymphoma</brief_summary>
	<brief_title>Oblimersen , Rituximab , Cyclophosphamide , Doxorubicin , Vincristine , Prednisone Treating Patients With Stage II , Stage III , Stage IV Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility safety oblimersen administer combination rituximab , cyclophosphamide , doxorubicin , vincristine , prednisone , term short-term long-term toxicity , patient previously untreated stage III IV extensive bulky stage II diffuse large B-cell lymphoma . - Determine maximum tolerate dose oblimersen administer regimen patient . Secondary - Determine remission rate failure-free , progression-free , overall survival patient treat regimen . OUTLINE : This nonrandomized , non-blinded , multicenter , dose-escalation study oblimersen . Patients receive CHOP-R* therapy comprise cyclophosphamide IV 15-45 minute , doxorubicin IV 5-10 minute , vincristine IV , rituximab IV 30-90 minute day 1 oral prednisone day 1-5 . Patients also receive oblimersen IV continuously day -4 3 . Treatment repeat every 21 day 6-8 course absence disease progression unacceptable toxicity . Patients discontinue treatment due unacceptable toxicity oblimersen may continue receive standard therapy comprise CHOP-R . NOTE : *Patients treat British Columbia Cancer Agency receive cyclophosphamide , doxorubicin , vincristine , rituximab day 1 2 prednisone . Cohorts 3-6 patient receive escalate dos oblimersen maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , least 10 patient treat dose level . Patients follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 19-28 patient accrue study within 5-10 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* CD20+ diffuse large Bcell lymphoma , include follow stage : Extensive stage II ( radioencompassable within single involved field candidate brief chemotherapy radiotherapy ) Bulky stage II ( single mass great 10 cm ) Stage III Stage IV NOTE : *Confirmed tissue biopsy Previously untreated disease Measurable disease At least 2 cm image study Circulating lymphoma cell great 5,000/mm^3 No history lymphoproliferative disorder No history indolent lymphoma No Tcell lymphoma No CNS involvement No posttransplantation lymphoproliferative disorder PATIENT CHARACTERISTICS : Age 19 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count least 1,500/mm^3 ( unless due bone marrow involvement lymphoma ) Platelet count least 100,000/mm^3 ( unless due splenomegaly bone marrow involvement lymphoma ) Hepatic Bilirubin great 3 mg/dL ( unless due lymphoma ) No know hepatitis B virus Renal Creatinine great 2 mg/dL ( unless due lymphoma ) Cardiovascular No cardiac contraindication doxorubicin therapy ( e.g. , abnormal contractility echocardiography ) History cardiac disease allow provided ejection fraction normal Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Adequate venous access HIV negative No malignancy within past 5 year except adequately treat nonmelanoma skin cancer , localize basal cell squamous cell skin cancer , curatively treat carcinoma situ cervix No neurological contraindication vincristine ( e.g. , peripheral neuropathy ) No active systemic infection No medical condition would compromise study treatment , add toxicity , impair assessment PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Prior radiotherapy localize basal cell squamous cell skin cancer use curative intent allow Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2005</verification_date>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
</DOC>